Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Dr. O'Connor on Acalabrutinib Versus Ibrutinib in MCL

January 3rd 2018

Owen O'Connor, MD, PhD, Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center, discusses acalabrutinib (Calquence) versus ibrutinib (Imbruvica) for the treatment of patients with mantle cell lymphoma

FDA Grants Priority Review to Frontline Brentuximab Vedotin for Hodgkin Lymphoma

January 2nd 2018

The FDA has granted a priority review to a supplemental biologics license application for brentuximab vedotin (Adcetris) in combination with Adriamycin, vinblastine, and dacarbazine (AVD) as a frontline treatment for advanced classical Hodgkin lymphoma.

Combination Checkpoint Therapy Gains Ground in AML and MDS

December 29th 2017

Rational combinations of immune checkpoint inhibitors with other standard antileukemic agents may be needed to improve the response rates, the durability of response, and the overall survival in patients with AML/MDS.

Plethora of New Drugs in AML Stirs Hope

December 27th 2017

After several decades without a new therapy, the approval of 4 treatments for acute myeloid leukemia over the span of just 4 months is either a total coincidence or an inevitable occurrence.

FDA Approval Sought for Ivosidenib in IDH1+ AML

December 26th 2017

A new drug application has been submitted for ivosidenib for patients with relapsed/refractory IDH1-mutant acute myeloid leukemia, according to a statement from Agios Pharmaceuticals, the company developing the targeted therapy.

FDA Updates Nilotinib CML Label With Discontinuation Provision

December 23rd 2017

The FDA has updated the label for nilotinib with a provision stipulating that patients with Philadelphia chromosome-positive chronic myeloid leukemia in the chronic phase who have received the BCR-ABL tyrosine kinase inhibitor for at least 3 years and have achieved specific predetermined criteria may be eligible to stop treatment.

Highlights from ASH 2017: Mantle Cell Lymphoma

December 23rd 2017

Investigational Treatment in Mantle Cell Lymphoma

December 23rd 2017

Future Therapy: Bruton's TKI Containing Combinations in MCL

December 23rd 2017

Allogeneic Transplantation in Mantle Cell Lymphoma

December 23rd 2017

Acalabrutinib in Relapsed Mantle Cell Lymphoma

December 23rd 2017

Ibrutinib in Relapsed Mantle Cell Lymphoma

December 23rd 2017

Understanding Relapse in Mantle Cell Lymphoma

December 23rd 2017

Maintenance Therapy in Mantle Cell Lymphoma

December 23rd 2017

Considerations for Autologous Stem Cell Transplantation

December 23rd 2017

Induction Therapy for Mantle Cell Lymphoma

December 23rd 2017

The Watch-and-Wait Approach in Mantle Cell Lymphoma

December 23rd 2017

The Value of MIPI and Ki-67 in Mantle Cell Lymphoma

December 23rd 2017

Considerations for Diagnosing Mantle Cell Lymphoma

December 23rd 2017

Classifying Mantle Cell Lymphoma

December 23rd 2017